Xeris Biopharma Holdings (LTS:0A8E) Net Income (Continuing Operations) : $-64.4 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Xeris Biopharma Holdings's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was $-19.0 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was $-64.4 Mil.

Xeris Biopharma Holdings Net Income (Continuing Operations) Historical Data

The historical data trend for Xeris Biopharma Holdings's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Net Income (Continuing Operations) Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-125.58

-91.14

-122.73

-94.66

-62.26

Xeris Biopharma Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-16.83	-19.84	-12.19	-13.39	-18.98

Xeris Biopharma Holdings Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.4 Mil.

Xeris Biopharma Holdings (LTS:0A8E) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Xeris Biopharma Holdings Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings (LTS:0A8E) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

XERS:USA 2B30:Germany

Address

180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

Xeris Biopharma Holdings (LTS:0A8E) Headlines

No Headlines